Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 6/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.59 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477147 | 1.00 | SLC1A1 (1.00) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL9418943 | 0.84 | SLC1A1 (0.70) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL6029513 | 0.81 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL6029508 | 0.81 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL5293587 | 0.80 | SLC1A1 (0.67) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL5279387 | 0.79 | SLC1A1 (0.65) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL5596021 | 0.79 | SLC1A1 (0.65) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL13621431 | 0.78 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL3471272 | 0.78 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL3470567 | 0.78 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103333079-A | Imino acid PET imaging agent, and preparation method and application thereof | GUANGDONG HUIXUAN PHARMACEUTICAL TECHNOLOGY CO LTD | 2013-10-02 | — | — | CN | disclosed |
| US-20030170653-A1 | Biological method for the production of tuliposide A and its intermediates | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-09-11 | — | — | US | disclosed |
| WO-2002101013-A2 | A BIOLOGICAL METHOD FOR THE PRODUCTION OF ALPHA-METHYLENE-GAMMA-BUTYROLACTONE AND ITS INTERMEDIATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170653-A1 | Biological method for the production of tuliposide A and its intermediates | ABAT, BCAT1, UGGT1 | SLC1A1 679/4885SLC1A2 511/4885SLC1A3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.